Authors
Latest:
Amy Robach on Factors Impacting Her Breast Cancer Treatment DecisionAmy Robach, breast cancer survivor and Good Morning America news anchor, describes her diagnosis of a 2 cm tumor in her right breast that appeared isolated on ultrasound and other subsequent scans.
Latest:
Oncology Nurse Navigators and Community Health Workers: Building Unique Relationships for Cancer Care, Part II of IIAmy Sebastian-Deutsch describes the potential for a collaborative relationship between Oncology Nurse Navigators and community health workers.
Latest:
Dr. Acuna-Villaorduna on the Increase of Early-Onset CRC DiagnosesAna Acuna-Villaorduna, MD, Heme/Oncology fellow at Montefiore Medical Center/Albert Einstein College of Medicine, discusses the increase of early-onset colorectal cancer, specifically in African-American and Hispanic populations.
Latest:
Triple Receptor-Negative Breast Cancer: Current and Future TreatmentsBreast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.
Latest:
Dr. Molina on Information for the Public on Kidney CancerAna M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, shares information that she feels the public should know about kidney cancer.
Latest:
Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial CancerAna Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits ManagementPayers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.
Latest:
Cancer Disparities Heighten Need to Recruit Hispanics for Clinical TrialsThe Hispanic population in the United States represents the fastest-growing segment of the population (expected to reach 30% of the nation's total by 2050), and faces significant cancer health disparities
Latest:
Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case ReportThis is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Latest:
Dr. Younes Discusses the Future of CAR T-Cell TherapyAnas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.
Latest:
Dr. Raptis on DRd in Newly Diagnosed Multiple MyelomaAnastasios Raptis, MD, a clinical assistant professor of medicine at the University of Pittsburgh School of Medicine Hillman Cancer Center, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) in the treatment of patients with newly diagnosed multiple myeloma.
Latest:
Dr. Dimou on Managing Disease Progression in NSCLCAnastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.
Latest:
Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate CancerIntermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.
Latest:
Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBCA review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.
Latest:
Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCLAndre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.
Latest:
Dr Goy on Updated Data From ZUMA-2 With Brexu-Cel in MCLAndre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.
Latest:
Goy Gives Insights Into the Future Management of Lymphoma and Multiple MyelomaDr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.
Latest:
Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCLAndre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.
Latest:
Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.
Latest:
Novel Therapy in Urothelial Carcinoma: An Evolving Treatment LandscapeClosing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
Latest:
Advice for Providers Treating Metastatic Colorectal CancerExperts provide advice for providers treating patients with metastatic colorectal cancer and highlight exciting potential combination treatments on the horizon.
